20,389 Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Mcdonald Capital Investors Inc. CA

Mcdonald Capital Investors Inc. CA lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 172,649 shares of the biopharmaceutical company’s stock after selling 20,389 shares during the quarter. Regeneron Pharmaceuticals accounts for about 10.7% of Mcdonald Capital Investors Inc. CA’s portfolio, making the stock its 2nd largest position. Mcdonald Capital Investors Inc. CA owned about 0.17% of Regeneron Pharmaceuticals worth $130,915,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in REGN. LCM Capital Management Inc grew its position in Regeneron Pharmaceuticals by 2.2% in the third quarter. LCM Capital Management Inc now owns 616 shares of the biopharmaceutical company’s stock worth $467,000 after acquiring an additional 13 shares in the last quarter. Arjuna Capital raised its position in Regeneron Pharmaceuticals by 3.2% during the first quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after purchasing an additional 14 shares during the period. Oakworth Capital Inc. raised its position in Regeneron Pharmaceuticals by 25.0% during the third quarter. Oakworth Capital Inc. now owns 70 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 14 shares during the period. Boyd Watterson Asset Management LLC OH lifted its stake in shares of Regeneron Pharmaceuticals by 1.4% in the 1st quarter. Boyd Watterson Asset Management LLC OH now owns 1,087 shares of the biopharmaceutical company’s stock valued at $840,000 after purchasing an additional 15 shares during the last quarter. Finally, Geneos Wealth Management Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 1.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 835 shares of the biopharmaceutical company’s stock valued at $645,000 after purchasing an additional 15 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $816.10 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $591.52 and a 1 year high of $859.34. The business has a 50 day simple moving average of $791.66 and a two-hundred day simple moving average of $737.08. The firm has a market capitalization of $84.02 billion, a PE ratio of 20.17 and a beta of 0.16.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. During the same period in the prior year, the company posted $12.81 EPS. The company’s quarterly revenue was up 16.7% compared to the same quarter last year. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 49.10 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is presently 9.29%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on REGN shares. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $758.00 to $779.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. The Goldman Sachs Group increased their price target on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the company a “buy” rating in a report on Friday, July 31st. Jefferies Financial Group increased their price target on Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Argus upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price target for the company in a research report on Thursday, October 1st. Finally, Royal Bank Of Canada lifted their price objective on shares of Regeneron Pharmaceuticals from $737.00 to $810.00 and gave the stock a “sector perform” rating in a research note on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $846.28.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron extended its agreement with the U.S. Biomedical Advanced Research and Development Authority (BARDA) to supply additional doses of Inmazeb, its Ebola treatment. The extension adds approximately $270 million in value and supports near-term revenue visibility. Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb for U.S. Preparedness
• Positive Sentiment: Strong third-quarter results from partner Kiniksa highlighted growing demand and blockbuster potential for Arcalyst, which is partnered with Regeneron. The update may reinforce expectations for increased royalty or collaboration-related contributions. Kiniksa jumps as Q3 results show blockbuster prospects for Regeneron-partnered Arcalyst
• Positive Sentiment: Regeneron released nearly four years of survival-benefit data for Libtayo, its cancer immunotherapy. Durable efficacy could support the drug’s commercial positioning and future adoption. Regeneron Pharmaceuticals Posts Nearly Four Years of Survival Benefit Data for Libtayo
• Neutral Sentiment: Analysts expect third-quarter earnings of approximately $16.19 per share, with results due October 30. Investors are also focused on Regeneron recording its full share of Dupixent profits with Sanofi for the first time, a potentially significant earnings catalyst but one already receiving attention ahead of the report. Regeneron Q3 earnings preview
• Neutral Sentiment: Recent commentary describes REGN as an increasingly diversified investment and a strong value stock. Reported short interest of zero shares provides no meaningful bearish signal, although the figure may reflect a data-reporting issue rather than actual market positioning. Has Regeneron Stock Become a Different Bet?

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $340,000.00. Following the transaction, the director owned 603 shares of the company’s stock, valued at $512,550. This represents a 39.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at approximately $1,362,400. The trade was a 31.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 8,093 shares of company stock worth $6,506,845. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.